GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on ...
Soy Nómada on MSN
Predict: What your SKIN say is wrong with your health
Your skin may reflect internal imbalances, lifestyle stressors, or chronic conditions—subtle signs that can reveal more about ...
TipRanks on MSN
Galapagos reports mixed late-stage results for TYK2 inhibitor GLPG3667 and eyes partnerships after dermatomyositis win
On December 18, 2025, Galapagos reported topline data from two Phase 3-enabling trials of its selective TYK2 inhibitor GLPG3667, showing that the GALARISSO dermatomyositis study met its primary ...
Love Island USA winner Amaya "Papaya" Espinal shared a look at her recovery after being hospitalized for abdominal pain and ...
Knight Therapeutics Inc. (TSX: GUD) ('Knight'), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved WYNZORA®, a white uniform cream containing ...
Extracorporeal membrane oxygenation (ECMO) technology has relative contraindications in haemorrhagic disease but remains an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback